作为预测过敏性鼻炎治疗反应的系统性炎症指数:一个前性的6个月队列研究
Başak Yalçıner1, Mehmet Ali Babademez2
1Department of Otolaryngology, Ankara City Hospital, Ankara, Turkey.
Ear, nose, & throat journal
|February 17, 2026
概括
系统性炎症指数,如中性粒细胞与淋巴细胞比率 (NLR) 和乙素细胞计数,可以预测过敏性鼻炎 (AR) 的治疗反应. 这些血液学标志物为监测AR活性和指导临床管理提供了具有成本效益的工具.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 过敏和临床免疫学
背景情况:
- 过敏性鼻炎 (AR) 越来越多地被视为一种全身炎症状况.
- 预测AR治疗结果的客观生物标志物有限,尽管通常使用症状得分.
- 系统性炎症指数 (SII),中性粒细胞与淋巴细胞的比率 (NLR),血小板与淋巴细胞的比率 (PLR),乙素细胞数和总免疫球蛋白E (IgE) 进行了评估.
研究的目的:
- 评估系统性炎症指数作为客观生物标志物的实用性,用于监测疾病活动和预测过敏性鼻炎 (AR) 治疗反应.
- 评估基线NLR,PLR,SII,乙氨基酸计数和IgE对AR患者在6个月的随访期内治疗结果的预测值.
主要方法:
- 一项前性队列研究,涉及105名中度至重度持久性AR患者和92名健康对照.
- 基线和6个月后的测量包括全血细胞计衍生指数 (NLR,PLR,SII),乙素细胞计数和血清总IgE.
- 使用全鼻症状评分和视觉模拟尺度评估症状严重程度;ROC分析确定了预测治疗反应的最佳切断值.
主要成果:
- 与对照人群相比,AR患者的基线NLR,PLR,SII和乙氨基酸细胞数量显著增加 (P < .001).
- 这些指数显著下降,与症状改善相关,并且在AR患者中明显大于对照组.
- 基线NLR>2.7显示出非响应最强的预测值 (灵敏度84%,特异性76%),而PLR,SII,乙素和IgE的升高也表明非响应风险增加. 总IgE对短期监测没有用处.
结论:
- 中性粒细胞与淋巴细胞的比率 (NLR),血小板与淋巴细胞的比率 (PLR),全身免疫炎症指数 (SII) 和乙素细胞数量是监测AR活性和预测治疗反应的有希望的生物标志物.
- 特别是NLR,可以作为AR管理中早期风险分层的简单,具有成本效益的工具.
- 这些发现支持将常规血液学标记纳入过敏性鼻炎的临床管理.
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.2K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.2K
02:06Allergic Reactions
32.6K
Overview
32.6K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.6K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.9K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.9K